Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 661 to 675 of 1809 results for nice guidelines

  1. Heart Failure: ACEi or ARBs (IND193)

    This indicator covers the percentage of patients with a current diagnosis of heart failure due to left ventricular systolic dysfunction, who are currently treated with an ACE-I or ARB. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM172

  2. Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable ID3981

    In development [GID-TA10912] Expected publication date: 16 July 2025

  3. Interim methods guide for developing service guidance 2014 (PMG8)

    Interim methods guide for developing service guidance 2014

  4. Heart failure: confirmation of diagnosis (IND192)

    This indicator covers the percentage of patients with a diagnosis of heart failure after (start date) which has been confirmed by an echocardiogram or by specialist assessment between 3 months before or 3 months after entering on to the register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM171

  5. Quality improvement resource for adult social care

    NICE quality improvement resource (QIR) for adult social care

  6. Chronic wounds: advanced wound dressings and antimicrobial dressings (ESMPB2)

    Summary of the evidence on advanced wound dressings and antimicrobial dressings for managing chronic wounds to inform local NHS planning and decision-making

  7. Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (TA209)

    Evidence-based recommendations on imatinib for treating unresectable or metastatic gastrointestinal stromal tumours in adults.

  8. Vortioxetine for treating major depressive episodes (TA367)

    Evidence-based recommendations on vortioxetine (Brintellix) for treating major depressive episodes in adults.

  9. Cenobamate for treating focal onset seizures in epilepsy (TA753)

    Evidence-based recommendations on cenobamate (Ontozry) for treating focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy that has not been adequately controlled with at least 2 antiseizure medicines.

  10. Therapeutic interventions after abuse and neglect

    them in decisions about their life. Useful links NICE guideline: Child abuse and neglect (NG76) . Additional information...

  11. Accessibility changes: notes for developers (ECD6)

    This is a summary of the most common accessibility changes we are making in guidelines, and why

  12. Guidance on the use of electroconvulsive therapy (TA59)

    Evidence-based recommendations on electroconvulsive therapy (ECT) for treating catatonia, prolonged or severe manic episodes or schizophrenia in adults.

  13. Mirabegron for treating symptoms of overactive bladder (TA290)

    Evidence-based recommendations on mirabegron (Betmiga) for treating overactive bladder in adults.

  14. Diabetes: annual albumin creatinine test (IND111)

    This indicator covers the percentage of patients with diabetes who have a record of an albumin creatinine ratio (ACR) test in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  15. The NICE public health guidance development process (third edition) (PMG5)

    The NICE public health guidance development process (third edition)